NeuroOne® Announces First Implant of OneRF™ Ablation Electrodes
- None.
- None.
Insights
The recent announcement by NeuroOne Medical Technologies Corporation concerning the first implant of its OneRF™ Ablation electrode represents a significant milestone in the field of functional neurosurgery. The integration of sEEG-guided RF ablation with temperature control into a single system presents a novel approach to treating neurological disorders such as epilepsy. This innovation could potentially streamline the surgical process by reducing the number of required surgeries and hospital stays.
From a medical research perspective, the dual-functionality of the electrodes, allowing for both recording and ablation, may lead to improved patient outcomes due to the precision it affords in identifying and treating affected nervous tissue. Furthermore, the added temperature control feature is an advancement that could minimize the risk of collateral damage during ablation procedures, enhancing patient safety. As the system has received FDA 510(k) clearance, its adoption could set a new standard in the treatment of neurological disorders that require ablation, potentially impacting the current practices in the field.
NeuroOne's entry into the brain ablation market with the OneRF™ Ablation System is strategically significant. The company's estimation of the market being at least $100M and rapidly growing indicates a robust commercial opportunity. The ability to address a large patient population with unmet clinical needs presents a potential for market expansion and increased revenue streams for NeuroOne.
Moreover, being first to market with this technology could provide NeuroOne with a competitive advantage, positioning it as a market leader in multi-functional diagnostic and therapeutic thin-film electrode technology. The market response to this innovation will be critical to watch, as it may influence investor sentiment and stock performance in the short to medium term. Future adoption rates by healthcare providers and the system's performance in a clinical setting will be key factors in determining its impact on the company's financial health.
The introduction of the OneRF™ Ablation System by NeuroOne, which is now part of a full line of thin-film electrode technology, represents a diversification of the company's product portfolio. This diversification is likely to be viewed positively by investors, as it reduces reliance on a single product and opens up additional revenue channels. The system's FDA clearance is an important regulatory milestone that may lead to increased investor confidence in the company's ability to navigate the complex medical device approval process.
It is important to monitor the company's financials in subsequent quarters to assess the impact of this product launch on the bottom line. The cost of research and development, marketing and sales efforts related to the new system will need to be balanced against the revenue generated to evaluate the product's profitability. Additionally, the company's claims of potential reductions in hospital stays and surgeries, if substantiated, could lead to cost savings for healthcare providers and insurers, potentially affecting the healthcare economics surrounding neurological treatments.
First to market FDA-cleared thin-film, sEEG-guided RF system capable of both recording electrical activity and ablating nervous tissue with the added benefit of temperature control
EDEN PRAIRIE, Minn., April 09, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the first implant of its OneRF™ Ablation electrode by doctors at a top ranked hospital in the US, as ranked by the US News & World Best Hospital Report in its 2023-2024 publication. The OneRF™ Ablation system has FDA 510(k) clearance for creation of radiofrequency (“RF”) lesions in nervous tissue for functional neurosurgical procedures.
“We are excited to announce that yesterday, doctors implanted Evo® sEEG-RF electrodes in a patient suffering from epilepsy. Once the monitoring identifies the areas of the brain that are causing seizures, the surgical team now has the option to use the same electrodes to perform an ablation utilizing NeuroOne’s RF generator. This capability provides the neurosurgeon an entirely new option for use in the appropriate patients and situation. Being first to market with this technology positions the Company as a market leader in offering multi-functional diagnostic and therapeutic thin-film electrode technology,” said Dave Rosa, CEO of NeuroOne. “As stated previously, we believe the technology has the potential to reduce hospital stays, number of surgeries, and adverse events, while offering significant clinical benefits including temperature control to enhance patient safety.”
The OneRF™ Ablation System is NeuroOne’s first device with a therapeutic indication and its third FDA 510(k)-cleared device. NeuroOne now boasts a full line of thin film electrode technology to address patients requiring diagnostic brain mapping procedures as well as RF ablation using the same sEEG electrode. In addition to the OneRF™ Ablation System, NeuroOne’s other FDA-cleared devices include the Evo® cortical and sEEG electrode product lines which are used primarily for stimulation, recording and monitoring of electrical activity in the brain for less than 30 days.
NeuroOne estimates the current brain ablation market to be at least
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit www.nmtc1.com.
Forward Looking Statements
This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward–looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "target," "seek," "contemplate," "continue, "focused on," "committed to" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the timing and occurrence of the ablation procedure, , the ability of the OneRF Ablation System to reduce hospital stays, reduce the number of surgeries, or reduce adverse events, business strategy, market size, potential growth opportunities, and future operations. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our partnerships may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions, labor shortages, risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company's capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks related to our ability to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading "Risk Factors" in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
“Caution: Federal law restricts this device to sale by or on the order of a physician”
Contact:
800-631-4030
ir@nmtc1.com
FAQ
What is the name of the company mentioned in the press release?
What is the ticker symbol for NeuroOne Medical Technologies ?
What is the FDA clearance status of the OneRF™ Ablation system?
What is the main benefit of the OneRF™ Ablation system mentioned in the PR?
What is the estimated size of the current brain ablation market worldwide according to NeuroOne?
